5-Bromo-2-chloroisonicotinic acid | CAS:886365-31-7

We serve 5-Bromo-2-chloroisonicotinic acid CAS:886365-31-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
5-Bromo-2-chloroisonicotinic acid

Chemical Name:5-Bromo-2-chloroisonicotinic acid
CAS.NO:886365-31-7
Synonyms:5-Bromo-2-chloroisonicotinic acid
5-Bromo-2-chloropyridine-4-carboxylic acid
 
Physical and Chemical Properties:
Density 1.9±0.1 g/cm3
Boiling Point 419.3±45.0 °C at 760 mmHg
Molecular Formula C6H3BrClNO2
Molecular Weight 236.451
Flash Point 207.4±28.7 °C
Vapour Pressure 0.0±1.0 mmHg at 25°C
Index of Refraction 1.630
 
Specification:
Appearance:Off-white crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 5-Bromo-2-chloroisonicotinic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Bromo-2-chloropyridine-4-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Bromo-2-chloroisonicotinic acid Use and application,5-Bromo-2-chloropyridine-4-carboxylic acid technical grade,usp/ep/jp grade.


Related News: The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant’s collection.Ethyl 2-bromopropionate manufacturer Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.3,5-Difluoro-2-methylbenzonitrile supplier 3-fluoroaniline vendor After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply.We have leading expertise in strategy and operational implementation of pre-approval access programs making pharmaceutical products under clinical development available for patients and Inceptua’s clinical trial services business offers high quality clinical comparator sourcing and manufacturing services with an agile global supply chain to ensure that products are delivered exactly when needed.